Shree Ganesh Remedies Ltd Reports Sharp Decline in Quarterly Financial Performance Amid Sector Challenges

Quarterly Financial Performance: A Sharp Downturn

The latest quarterly results reveal a significant weakening in Shree Ganesh Remedies’ financial health. Net sales for the quarter stood at ₹21.11 crores, the lowest recorded in recent periods, signalling a contraction in top-line momentum. This decline is particularly concerning given the company’s prior growth phases, where revenue expansion was a key driver of shareholder value.

Profitability metrics have also suffered. The Profit Before Depreciation, Interest, and Taxes (PBDIT) dropped to ₹6.74 crores, marking a new low for the company. Correspondingly, Profit After Tax (PAT) plunged by 43.0% to ₹3.09 crores, underscoring the pressure on net earnings. Earnings Per Share (EPS) followed suit, falling to ₹2.41, the lowest quarterly figure in recent memory.

Return on Capital Employed (ROCE) for the half-year period has declined to 16.18%, the lowest level recorded, indicating diminished efficiency in generating returns from invested capital. This is a critical metric for investors assessing the company’s operational effectiveness and long-term viability.

Financial Trend Shift: From Negative to Very Negative

MarketsMojo’s proprietary financial trend score for Shree Ganesh Remedies has deteriorated sharply, falling from -13 to -22 over the past three months. This shift from a negative to a very negative trend reflects worsening fundamentals and heightened risk factors. The company’s debt-equity ratio remains low at 0.24 times, which is a positive sign of limited leverage; however, rising interest expenses have offset this advantage.

Interest costs for the nine-month period have surged by 49.44% to ₹2.69 crores, exerting additional strain on profitability. The increase in interest burden, despite low leverage, suggests either higher borrowing costs or increased utilisation of debt facilities, which could further pressure margins if unchecked.

Stock Price and Market Performance

Despite the financial setbacks, Shree Ganesh Remedies’ stock price has shown modest resilience in the short term. The current price is ₹424.00, slightly up by 0.68% from the previous close of ₹421.15. The stock traded within a range of ₹409.95 to ₹430.00 during the day, remaining near its 52-week low of ₹399.95 but far below its 52-week high of ₹950.00.

However, the company’s longer-term returns paint a more sobering picture. Over the past year, the stock has declined by 38.68%, significantly underperforming the Sensex, which gained 6.56% over the same period. This underperformance extends to the year-to-date period, with the stock down 8.46% compared to the Sensex’s 4.32% loss. On a more positive note, the stock has delivered strong returns over the three- and five-year horizons, with gains of 65.18% and 215.42% respectively, outperforming the Sensex’s 33.80% and 66.82% returns. This suggests that while recent quarters have been challenging, the company has demonstrated robust growth over the medium term.

Industry Context and Sectoral Challenges

The Pharmaceuticals & Biotechnology sector has faced a mixed environment recently, with regulatory pressures, pricing challenges, and supply chain disruptions impacting many players. Shree Ganesh Remedies’ deteriorating financial trend is reflective of these broader headwinds, compounded by company-specific issues such as rising interest expenses and declining operational efficiency.

Investors should note that the company’s low debt-equity ratio remains a relative strength, providing some buffer against financial distress. Nonetheless, the sharp contraction in profitability and sales growth raises concerns about the sustainability of current operations and the ability to invest in future growth initiatives.

Mojo Score and Analyst Ratings

Reflecting the deteriorating fundamentals, Shree Ganesh Remedies’ Mojo Score has declined to 23.0, with the Mojo Grade downgraded from Sell to Strong Sell as of 12 January 2026. This downgrade signals heightened caution among analysts and suggests that the stock currently carries elevated risk relative to its peers.

The company’s Market Cap Grade remains low at 4, indicating limited market capitalisation strength. These ratings underscore the need for investors to carefully reassess their exposure to the stock, particularly in light of the recent negative financial trend and sectoral uncertainties.

Outlook and Investor Considerations

Shree Ganesh Remedies Ltd is at a critical juncture, with recent quarterly results highlighting significant operational and financial challenges. While the company’s low leverage and historical growth record provide some positives, the steep declines in revenue, profitability, and returns on capital cannot be overlooked.

Investors should weigh these factors against the broader sector dynamics and consider alternative investment opportunities that may offer more stable growth and stronger fundamentals. The company’s current valuation and market performance suggest that a cautious approach is warranted until there is clear evidence of a turnaround or stabilisation in financial metrics.

Monitoring upcoming quarterly results and management commentary will be essential to gauge whether Shree Ganesh Remedies can arrest the decline and return to a sustainable growth path.

Unlock special upgrade rates for a limited period. Start Saving Now →